Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
06/2003
06/17/2003CA2220698C N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same
06/17/2003CA2100462C Non-depleting cd4-specific monoclonal antibodies for the treatment of insulin-dependent diabetes mellitus (iddm)
06/14/2003CA2364985A1 Imidazo(2,1-b)thiadiazole sulfonamides
06/12/2003WO2003048772A2 Detection of autoantibodies reactive with pancreatic islet cell antigenic molecules and/or insulin
06/12/2003WO2003048360A1 NOVEL PROTEINS BINDING TO MAMMALIAN TARGET OF RAPAMYCIN (mTOR) AND GENES THEREOF
06/12/2003WO2003048359A1 Markers for sugar/lipid metabolic disorders and utilization thereof
06/12/2003WO2003048358A1 Adipocyte differentiation-associated gene and protein
06/12/2003WO2003048336A2 Cultured cells from pancreatic islets
06/12/2003WO2003048195A2 Glucose dependant release of insulin from glucose sensing insulin derivatives
06/12/2003WO2003048180A1 Crystalline form of a ribofuranosyluronamide derivative; a human adenosine a2a receptor agonist
06/12/2003WO2003048162A1 Novel crystalline compound
06/12/2003WO2003048160A1 Ring fused pyrazole derivatives
06/12/2003WO2003048156A1 Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine
06/12/2003WO2003048149A1 Processing method of lactonization in the preparation of statins
06/12/2003WO2003048148A2 Statin-like compounds
06/12/2003WO2003048141A1 Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof
06/12/2003WO2003048140A1 Azole compound and medicinal use thereof
06/12/2003WO2003048130A2 Peroxisome proliferator activated receptor agonists
06/12/2003WO2003048129A1 Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same
06/12/2003WO2003048117A2 Propanolaminomethyltetralines, their preparation and pharmaceutical composition comprising same
06/12/2003WO2003048116A2 Esters and amides as ppar-alpha agonists ____________
06/12/2003WO2003048109A1 Novel glucagon antagonists
06/12/2003WO2003048108A2 Compounds for treatment of inflammation, diabetes and related disorders
06/12/2003WO2003047627A1 Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a thiazolidinedione derivative, and a use thereof for treating diabetes
06/12/2003WO2003047626A1 Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
06/12/2003WO2003047618A2 Immunotherapeutic methods and systems
06/12/2003WO2003047616A1 Migration of hematopoietic stem cells and progenitor cells to th e liver
06/12/2003WO2003047615A1 Dexar agonists and antagonists for use in the treatment of metabolic disorders
06/12/2003WO2003047614A1 Agonist and antagonists of redax for the treatment of metabolic disorders
06/12/2003WO2003047611A2 Ptp10d, tec and edtp involved in triglycerid-metabolism
06/12/2003WO2003047607A1 Medicinal compositions containing human amnion-origin cells
06/12/2003WO2003047597A1 Combination of crystalline form of a ribofuranosyluronamide derivative and tiotropium salt
06/12/2003WO2003047595A1 Pharmaceutical compositions comprising active vitamin d compounds
06/12/2003WO2003047588A1 Kit for reducing aching caused by pde-v inhibitors
06/12/2003WO2003047574A1 Pharmaceutical composition comprising a derivative of 5-phenoxyalkyl-2,4-thiazolidinedione type and a 4-oxobutanoic acid
06/12/2003WO2003047573A1 Insulin resistance improving agents
06/12/2003WO2003047568A1 N-aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity
06/12/2003WO2003047561A1 Use of 4-oxobutanoic acid derivatives in the treatment of inflammation
06/12/2003WO2003047553A1 Synthesis of small particles
06/12/2003WO2003047516A2 Pyrimidine compounds
06/12/2003WO2003047499A2 Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
06/12/2003WO2003047421A2 Methods and reagents for diagnosis and treatment of diabetes
06/12/2003WO2003047417A2 Ep4 receptor agonist, compositions and methods thereof
06/12/2003WO2003047367A1 Solid and stable creatine/citric acid composition(s) and compositions containing carbohydrate(s) or hydrates thereof, method for the production and use thereof
06/12/2003WO2003005962A3 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate
06/12/2003WO2002064094A3 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
06/12/2003WO2002057465A3 Method for producing polyunsaturated fatty acids, novel biosynthesis genes and novel plant expression constructs
06/12/2003US20030109723 Processing method of lactionization in the preparation of statins
06/12/2003US20030109700 Antilipemic agents, anticholesterol agents, cardiovascular disorders, antiischemic agents
06/12/2003US20030109671 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
06/12/2003US20030109576 Tartrate salts of (r) -3-n,n- dicyclobutylamino-8-fluoro-3,4-dihydro-2h-1- benzopyran-5-carboxamide
06/12/2003US20030109570 Activate a peroxisome proliferator-activated receptor (PPAR) alpha or gamma which is an intranuclear transcription factor. The compound may be used as an active ingredient to give a drug for preventing or treating a variety of diseases
06/12/2003US20030109569 Amorphous, pharmaceutically acceptable atorvastatin salts, especially the calcium salt, are prepared from atorvastatin lactone or from a compound of formula (I) mixture of amorphous and crystalline forms of the atorvastatin salt. HMG-CoA
06/12/2003US20030109564 Treating: allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep
06/12/2003US20030109562 Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1, 6,9-trioxa-3-aza-cyclopenta[a]naphthalene
06/12/2003US20030109558 Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
06/12/2003US20030109556 Melanocortin receptor ligands
06/12/2003US20030109545 Their solvates and/or hydrates exhibiting an affinity and a selectivity for arginine-vasopressin V1b receptors or for both V1b and V1a receptors.
06/12/2003US20030109532 Modulators of dopamine neurotransmission
06/12/2003US20030109530 Diabetes, insulin resistance, dyslipidemia, obesity, high blood pressure, atherosclerosis, retinopathies and neurodegenerative disorders; synthesis by reacting a biguanide with an aldehyde, semiacetal or acetal in presence of acid catalyst
06/12/2003US20030109518 Substituted 1,4-benzodiazepines and uses thereof
06/12/2003US20030109497 Novel imidazolidine derivatives, their preparation and their use
06/12/2003US20030109490 Composite stimulating iNOS enzyme which induce immuno-reactant nitric oxide synthesis and process for preparing the same
06/12/2003US20030109449 Gastrointestinal tissue are described. Its formulation as a pharmaceutical, and its therapeutic and related uses in treating bowel tissue, are described. Also described are methods of identifying antagonist of glucogen-like
06/12/2003US20030109437 Peptides and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides derived from the amino acid sequences of such
06/12/2003US20030109435 Methods of inhibiting amyloid toxicity
06/12/2003US20030109429 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
06/12/2003US20030108928 MID 241 receptor, a novel G-protein coupled receptor
06/12/2003US20030108904 Novel scavenger receptors
06/12/2003US20030108619 Synergistic mixture of casein polypeptide to promote calcium absorption and genistein which inhibits bone resorption and promotes osteogenesis; prevent decrease in bone density and onset of osteoporosis
06/12/2003US20030108591 Mixture of flavonoids, vegetable protein and sterols
06/12/2003US20030108559 Induction immunology response; cardiovascular disorders, anticholesterol agents
06/12/2003US20030108558 Anticholesterol agents; rheumatic diseases; mutiple sclerosis; antidiabetic agents; administering protein extracted from animal liver
06/12/2003US20030108540 Inducing apoptosis in tissues; binding antibodies
06/12/2003US20030108538 LLG polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies
06/12/2003US20030108510 Synergistic mixture of rutin, escin and bufemin; branching of arteries, veins
06/12/2003CA2469524A1 Adipocyte differentiation-related gene and protein
06/12/2003CA2469385A1 Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
06/12/2003CA2469228A1 Azole compound and medicinal use thereof
06/12/2003CA2469227A1 New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
06/12/2003CA2469119A1 Pharmaceutical compositions comprising active vitamin d compounds
06/12/2003CA2469078A1 Immunotherapeutic methods and systems
06/12/2003CA2468991A1 Methods and reagents for diagnosis and treatment of diabetes
06/12/2003CA2468967A1 N-aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity
06/12/2003CA2468944A1 Migration of hematopoietic stem cells and progenitor cells to the liver
06/12/2003CA2468927A1 Ring fused pyrazole derivatives
06/12/2003CA2468846A1 Peroxisome proliferator activated receptor agonists
06/12/2003CA2468827A1 Insulin resistance improving agents
06/12/2003CA2468349A1 Pyrimidine compounds
06/12/2003CA2466751A1 Ep4 receptor agonist, compositions and methods thereof
06/11/2003EP1318149A1 Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing them
06/11/2003EP1317924A1 Kit for reducing aching caused by pde-v inhibitors
06/11/2003EP1317488A2 Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine)
06/11/2003EP1317486A1 Interferon-alpha induced gene
06/11/2003EP1317485A2 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
06/11/2003EP1317483A2 Variants of allergenic proteins of the group 2 of dermatophagoides
06/11/2003EP1317479A2 Methods and compositions for diseases associated with amyloidosis
06/11/2003EP1317465A1 Purine derivatives
06/11/2003EP1317459A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
06/11/2003EP1317454A2 Caspase inhibitors and uses thereof
1 ... 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 ... 1298